Hopp til hovedinnhold

Farmakologi
- Forgiftninger
  - Toksisitet, klinikk og behandling ved overdosering av legemidler
    - Toksisitet, klinikk og behandling: Legemidler uten egen omtale
      Adefovir
      Amylmetakresol
      Anifrolumab
      Arsentrioksid
      Asfotase
      Ataluren
      Bazedoksifen
      Betain
      Boceprevir
      Burosumab
      Cannabidiol
      Cimicifugae rhizoma (rotstokk av klaseormedrue)
      Daklatasvir
      Daklizumab
      Danaparoid
      Dasabuvir
      Deferasiroks
      Deferipron
      Dekstropropoksyfen–paracetamol
      Didanosin
      Digitoksin
      Ditranol
      Djevelklorot
      Dokosanol
      Doripenem
      Eføyblad
      Ekstrakt fra melbær og bjørk
      Eluksadolin
      Enfuvirtid
      Ergotamin
      Etidronat
      Etilefrin
      Famciklovir
      Fentolamin
      Fezolinetant
      Fluocinolonacetonid
      Fosamprenavir‌‍‍‍‌‍‌‍‌‍‍‌‌‍‌‌‍‍‌‌‍‍‍‍‍‍‍‍‌‌‍‌‌‍‍‌‍‍‌‌‌‌‍‌‍‍‌‍‍‌‌‍‍‍‍‍‍‌‍‍‌‍‌‍‌‌‌‍‌‍‍‍‍‍‍‍‍‌‌‌‌‌‌‌‍‌‌‍‍‌‌‍‍‌‍‍‌‌‍‍‌‌‌‍‌‌‌‍‍‌‌‍‌‍‌‌‌‍‌‌‍‍‌‌‌‍‌‍‌‌‍‌‍‌‌‍‌‌‌‌‌‍‌‍‌‌‌‌‍‌‌‌‍‍‌‌‌‍‌‌‌‌‍‍‌‌‍‌‍‍‍‌‍‍‌‌‍‌‌‌‌‍‌‌‌‍‌‍‌‌‍‌‌‍‌‍‌‍‌‍‌‌‍‌‌‍‌‌‌‍‌‍‌‍‌‍‌‍‍‌‍‌‌‌‌‍‌‌‍‌‌‌‌‍‌‌‍‌‍‌‍‌‌‍‌‍‌‍‌‍‌‍‌‍‌‍‍‍‌‌‌‍‌‌‌‍‌‌‌‌‌‌‌‌‍‍‌‌‌‌‍‌‌‍‍‌‍‌‍‌‌‍‌‌‍‌‌‌‌‍‍‌‌‍‍‌‍‌‌‍‌‌‍‌‌‌‍‍‌‍‌‌‌‍‌‌‌‌‌‌‌‍‌‍‌‍‌‌‍‌‌‍‌‌‌‌‌‌‌‍‌‌‍‍‌‌‍‍‌‍‌‍‍‌‌‍‌‌‌‌‍‌‌‌‍‌‍‌‌‍‌‌‍‌‍‌‍‌‍‌‌‍‌‌‍‌‌‌‍‌‍‌‍‌‍‌‍‍‌‍‌‌‌‌‍‌‌‍‌‌‌‌‍‌‌‍‌‍‌‍‌‌‍‌‍‌‍‌‍‌‍‌‍‌‍‍‍‌‍‌‌‌‍‌‌‌‍‌‌‌‌‌‌‌‌‍‍‌‌‌‌‍‌‌‍‍‌‍‌‍‌‌‍‌‍‌‌‍‌‌‌‌‍‍‌‌‍‍‌‍‌‌‍‌‌‍‌‌‍‌‍‌‌‍‌‌‌‍‌‌‌‍‌‌‌‍‌‌‌‍‍‌‌‌‍‌‍‌‌‌‌‌‌‌‌‍‍‌‍‌‍‍‌‌‌‍‍‌‍‌‌‌‍‌‍‍‌‌
      Foslevodopa
      Gadopiklenol
      Glasdegib
      Glyserolfenylbutyrat
      Hestekastanje
      Imlifidase
      Indinavir
      Ingenolmebutat
      Inotersen
      Isradipin
      Kapmatinib
      Kargluminsyre
      Karisoprodol
      Kasirivimab–imdevimab
      Katumaksomab
      Klodronat
      Klormetin
      Krizanlizumab
      Metyltioniniumklorid
      Lepirudin
      Levobupivakain
      Lodoxamid
      Lomitapid
      Malation
      Matrem
      Metakolin
      Metreleptin
      Metylskopolamin
      Migalastat
      Miglustat
      Mosunetuzumab
      Muromonab-CD3
      Nateglinid
      Natriumfenylbutyrat
      Necitumumab
      Neratinib
      Netilmicin
      Niklosamid
      Nitisinon
      Nusinersen
      Ofloksacin
      Olaratumab
      Ombitasvir-paritaprevir-ritonavir
      Onasemnogenabeparvovek
      Osilodrostat
      Papaverin
      Para-aminosalisylsyre
      Pegcetakoplan
      Pegunigalsidase alfa
      Pemigatinib
      Peppermynteolje
      Piracetam
      Pivampicillin
      Polyøstradiolfosfat
      Prasteron
      Pyrvin
      Racekadotril
      Ranitidin
      Ravulizumab
      Regadenoson
      Remimazolam
      Retigabin
      Rimeksolon
      Risdiplam
      Rosiglitazon
      Rosmarinolje
      Sakinavir
      Sapropterin
      Sarilumab
      Satralizumab
      Sebelipase alfa
      Sibutramin
      Siltuksimab
      Simeprevir
      Sinekatekiner (grønn te-ekstrakt)
      Sitaksentan
      Spesolimab
      Spiramycin
      Stavudin
      Sulindak
      Sutimlimab
      Tafasitamab
      Talimogenlaherparepvek
      Teikoplanin
      Telaprevir
      Telbivudin
      Tiklopidin
      Tiksagevimab–cilgavimab
      Tildrakizumab
      Tipranavir
      Trandolapril
      Trimetreksat
      Trioksalen
      Urokinase
      Valerianarot
      Velmanase alfa
      Vericiguat
      Voklosporin
      Volanesorsen
      Yohimbin
      Zikonotid

Tildrakizumab

Forfattere:

Barbro Johanne Spillum; Kristin Solberg Swahn og Dag Jacobsen

Åpne alle underkapitler

© 2026, Foreningen for utgivelse av Norsk legemiddelhåndbok

Postboks 5070 Majorstuen

0301 Oslo

Besøksadresse:

Slemdalsveien 1

Telefon: 953 61 653

E-post: post@legemiddelhandboka.no

Om oss